M&A

M&A

Alembic Pharma acquires UK-based Utility Therapeutics for $12-M

BSE Announcement   Daijiworld  

Vadodara-based, publicly listed Alembic Pharmaceuticals has acquired UK-based Utility Therapeutics for USD 12 million, marking an entry into the American branded pharmaceuticals market.Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The acquisition will allow Alembic to commercialise Utility’s FDA-approved drug Pivya (pivmecillinam), used to treat uncomplicated urinary tract infections (UTIs) in women. The drug was approved by the US Food and Drug Administration (USFDA) in April 2024 and is expected to hit the American market in the fourth quarter of 2025.